
Marco Feligioni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/991081/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Considerations around the SARS-CoV-2 Spike Protein with Particular Attention to COVID-19 Brain Infection and Neurological Symptoms. ACS Chemical Neuroscience, 2020, 11, 2361-2369.	1.7	75
2	c-Jun N-terminal Kinase Regulates Soluble Aβ Oligomers and Cognitive Impairment in AD Mouse Model. Journal of Biological Chemistry, 2011, 286, 43871-43880.	1.6	74
3	Obstacles against the Marketing of Curcumin as a Drug. International Journal of Molecular Sciences, 2020, 21, 6619.	1.8	62
4	Protein SUMOylation modulates calcium influx and glutamate release from presynaptic terminals. European Journal of Neuroscience, 2009, 29, 1348-1356.	1.2	60
5	SUMO: a (Oxidative) Stressed Protein. NeuroMolecular Medicine, 2013, 15, 707-719.	1.8	55
6	Crosstalk between JNK and SUMO Signaling Pathways: deSUMOylation Is Protective against H2O2-Induced Cell Injury. PLoS ONE, 2011, 6, e28185.	1.1	50
7	Ultrastructural localisation and differential agonist-induced regulation of AMPA and kainate receptors present at the presynaptic active zone and postsynaptic density. Journal of Neurochemistry, 2006, 99, 549-560.	2.1	43
8	Age-related changes of protein SUMOylation balance in the AβPP Tg2576 mouse model of Alzheimer's disease. Frontiers in Pharmacology, 2014, 5, 63.	1.6	42
9	Presynaptic c-Jun N-terminal Kinase 2 regulates NMDA receptor-dependent glutamate release. Scientific Reports, 2015, 5, 9035.	1.6	41
10	InÂvitro exposure to nicotine induces endocytosis of presynaptic AMPA receptors modulating dopamine release in rat nucleus accumbens nerve terminals. Neuropharmacology, 2012, 63, 916-926.	2.0	37
11	Trafficking of presynaptic AMPA receptors mediating neurotransmitter release: Neuronal selectivity and relationships with sensitivity to cyclothiazide. Neuropharmacology, 2006, 50, 286-296.	2.0	36
12	Targeting SUMO-1ylation Contrasts Synaptic Dysfunction in a Mouse Model of Alzheimer's Disease. Molecular Neurobiology, 2017, 54, 6609-6623.	1.9	26
13	Free d-aspartate triggers NMDA receptor-dependent cell death in primary cortical neurons and perturbs JNK activation, Tau phosphorylation, and protein SUMOylation in the cerebral cortex of mice lacking d-aspartate oxidase activity. Experimental Neurology, 2019, 317, 51-65.	2.0	24
14	Extracellular protons differentially potentiate the responses of native AMPA receptor subtypes regulating neurotransmitter release. British Journal of Pharmacology, 2005, 144, 293-299.	2.7	20
15	SUMOylation Regulates TDP-43 Splicing Activity and Nucleocytoplasmic Distribution. Molecular Neurobiology, 2021, 58, 5682-5702.	1.9	19
16	A Novel Pharmacological Protective Role for Safranal in an Animal Model of Huntington's Disease. Neurochemical Research, 2021, 46, 1372-1379.	1.6	14
17	The pivotal role of SUMO-1-JNK-Tau axis in an in vitro model of oxidative stress counteracted by the protective effect of curcumin. Biochemical Pharmacology, 2020, 178, 114066.	2.0	11
18	SUMO modulation of protein aggregation and degradation. AIMS Molecular Science, 2015, 2, 382-410.	0.3	11

Marco Feligioni

#	Article	IF	CITATIONS
19	The selective disruption of presynaptic JNK2/STX1a interaction reduces NMDA receptor-dependent glutamate release. Scientific Reports, 2019, 9, 7146.	1.6	10
20	Retinal ganglion cell loss in an ex vivo mouse model of optic nerve cut is prevented by curcumin treatment. Cell Death Discovery, 2021, 7, 394.	2.0	7
21	Effect of lobeglitazone on motor function in rat model of Parkinson's disease with diabetes co-morbidity. Brain Research Bulletin, 2021, 173, 184-192.	1.4	6
22	SUMOylation in Neuroplasticity and Neurological Disorders. NeuroMolecular Medicine, 2013, 15, 637-638.	1.8	4